市場調査レポート - 55496
世界の抗菌剤市場：R&Dパイプライン・市場分析・競合環境 The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape
発行
Arrowhead Publishers
出版日
2007年08月28日 ページ情報
英文 126 Pages
価格
世界の抗菌剤市場：R&Dパイプライン・市場分析・競合環境
The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape
出版日: 2007年08月28日
ページ情報: 英文 126 Pages
世界の抗感染市場は現在665億米ドルとなっており、そのうち抗菌剤は売上の半数以上を占めています。抗菌剤市場は2012年までに450億円に拡大すると見込まれています。
医療業界を専門とする米国の調査会社 Arrowhead Publishers (本社：ミネソタ州)
では、世界の抗菌剤市場について調査分析し、特にR&Dパイプライン・市場分析・競合環境についてまとめた報告書 "The Global
Antibacterials Market: R&D Pipelines, Market Analysis and Competitive
Landscape" を発行いたしました。
当報告書では、抗菌剤を分類し、それぞれの市場概要と主な製品、臨床上の効能とマーケティング、現在の市場動向などについて、概略下記の内容でお届けいたします。
第1章 エグゼクティブサマリー
第2章 細菌性疾患のイントロダクション
A群連鎖球菌
B群連鎖球菌
肺炎球菌
インフルエンザ菌
髄膜炎菌
メチシリン耐性黄色ブドウ球菌
第3章 患者の人口統計
第4章 主要成長牽引因子
薬剤耐性
新しい治療法
患者人口統計
ワクチン
臨床的成功の可能性
感染症に関連する間接コスト
第5章 主要成長阻害因子
過剰処方
抗生物質の耐性による短期的細菌性薬剤ライフサイクル
抗生物質の急な利用
ジェネリック医薬品
治療法とワクチン
第6章 市場
世界抗感染薬市場
市場区分
世界の抗菌剤市場
主要企業
市場動向
第7章 主な薬剤クラス
アミノグリコシド
カルバペネム
セファロスポリン
グリコペプチド
ケトライド
ポロペプチド
マクロライド
ペニシリン
オキサゾリジノン
キノロン
第8章 主要ブランド
第9章 今後のブランド動向
第10章 主要企業プロファイル
Advanced Life Sciences
Arpida Ltd
Basilea Pharmaceutica AG
Cerexa Inc.
Cubist Pharmaceuticals, Inc.
Targanta Therapeutics Crop.
Theravance
付録
図表
Abstract
The global anti-infective market is currently valued at US$66.5 billion with
antibacterial agents accounting for over 50% of sales. The antibacterial
market is set to grow to over US$45.0 billion by 2012, driven by the uptake of
newer antibacterial agents such as glycopeptides and carbapenems which
demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.
Pharmaceutical companies continue to develop a new generation of antibacterial
agents such as cephalosporins, macrolides and quinolones to overcome the major
issue of drug resistance. In addition, a number of new drug classes such as
dihydrofolate reductase inhibitors (DHFR) are under evaluation which are
effective in multi drug resistant organisms.
This report examines each of the antibacterial classes in turn, assessing the
market potential and application in hospital and community-acquired infections.
The following product classes are analyzed in this report:
aminoglycosides
carbapenems
cephalosporins
dihydrofolate reductase inhibitors
glycopeptides
ketolides
lipopeptides
macrolides
penicillins
oxazolidinones
pleuromutulins
quinolones
The report assesses the overall antibacterial market, key classes and the
drivers and resistors influencing their prescription. The report provides an
overview of key products in each category, summarizing their clinical efficacy
and marketing position. The overview of the current market is given in terms
of segmentation and by leading players and their products and analyzes market
trends.
The report also examines promising pipeline products and their potential
impact on the prescription of current and new antibacterial agents and the
future of the antibacterial market.
Key Features of this report:
Overview of the antibacterial market, including the main infectious
agents, therapeutic drug classes and key players.
In-depth analysis of different classes of antibacterial agents, including
leading antibacterial agents and a summary of leading brands within each class.
Comprehensive facts and figures for the antibacterial market, including
main players and drug class break-downs.
Future trends in the antibacterial marketplace, driven by drug resistance
and patient demographics.
Outlook for the antibacterial market, including the emergence of novel
therapies and the impact of generics.
Table of Contents
1 EXECUTIVE SUMMARY
2 INTRODUCTION TO BACTERIAL DISEASES
2.1 Group A Streptococcus (GAS)
2.2 Group B Streptococcus (GBS)
2.3 Streptococcus pneumoniae
2.4 Haemophilus Influenzae
2.5 Neisseria Meningitidis
2.6 Methicillin Resistant Staphylococcus Aurens (MRSA)
3 PATIENT DEMOGRAPHICS
3.1 Group A Streptococcus (GAS) Patient Statistics
3.2 Group B Streptococcus (GBS) Patient Statistics
3.3 Streptococcus pneumoniae Patient Statistics
3.4 Haemophilus Influenzae Patient Statistics
3.5 Neisseria Meningitidis Patient Statistics
3.6 MRSA Patient Statistics
4 KEY DRIVERS
4.1 Drug Resistance
4.2 New Treatments
4.3 Patient Demographics
4.4 Vaccines
4.5 Potential for Clinical Success
4.6 Indirect Cost Associated with Infectious Diseases
5 KEY RESISTORS
5.1 Over-prescription
5.2 Antibiotic Resistance Leading to Short Antibacterial Drug Lifecycles
5.3 Acute Use of Antibiotics
5.4 Generics
5.5 Curative Therapies and Vaccines
6 THE MARKET
6.1 The Global Anti-infective Market
6.2 Market Segments
6.3 Global Antibacterial Market
6.3.1 Cephalosporin Antibiotics
6.3.2 Macrolide Antibiotics
6.3.3 Penicillin Antibiotics
6.3.4 Quinolone Antibiotics
6.3.5 Other Antibiotics
6.4 The Major Players
6.4.1 Antibacterial Major Players in 2006
6.4.2 Antibacterial Major Players in 2012
6.5 Market Trends
6.5.1 Antibacterial Agents by 2012
7 LEADING ANTIBACTERIAL DRUG CLASSES
7.1 Aminoglycosides
7.2 Carbapenems
7.3 Cephalosporins
7.4 Glycopeptide
7.5 Ketolide
7.6 Lipopeptide
7.7 Macrolides
7.8 Penicillins
7.9 Oxazolidinones
7.10 Pleuromutilins
7.11 Quinolone
8 LEADING BRANDS
8.1 Aminogylcoside Antibiotics
8.1.1 Tygacil (Wyeth)
8.1.2 Leading Aminoglycoside Sales Forecasts
8.2 Carbapenem Antibiotics
8.2.1 Finibax (Shionogi/ Johnson & Johnson/[Peninsula])
8.2.2 Merrem/Meronem (AstraZeneca/Sumitomo Pharmaceuticals)
8.2.3 Primaxin/Tieman (Merck & Co.)
8.2.4 Leading Carbapenem Sales Forecasts
8.3 Cephalosporins
8.3.1 Ceftin/Zinnat (GlaxoSmithKline)
8.3.2 Flumarin (Shionogi)
8.3.3 Omnicef/Cefzon (Abbott Laboratories/Astellas)
8.3.4 Rocephin (Roche)
8.3.5 Leading Cephalosporin Sales Forecasts
8.4 Glycopeptide Antibiotics
8.4.1 Vancomycin (Shionogi/ViroPharm/[Eli Lilly])
8.4.2 Targocid (Sanofi-Aventis/Astellas)
8.4.3 Leading Glycopeptide Sales Forecasts
8.5 Ketolide Antibiotics
8.5.1 Ketek (Sanofi-Aventis/Astellas)
8.5.2 Leading Ketolide Sales Forecasts
8.6 Lipopeptide Antibiotics
8.6.1 Cubicin (Cubist Pharmaceuticals/Novartis)
8.6.2 Leading Lipopeptide Sales Forecasts
8.7 Macrolide Antibiotics
8.7.1 Biaxin/Biaxin XL (Abbott Laboratories)
8.7.2 Zithromax/Zmax (Pfizer)
8.7.3 Macrolide Sales Forecasts
8.8 Oxazolidinone Antibiotics
8.8.1 Zyvox/Zyvoxid (Pfizer)
8.8.2 Leading Oxazolidinone Sales Forecasts
8.9 Penicillin Antibiotics
8.9.1 Augmentin (GlaxoSmithKline)
8.9.2 Zosyn/Tazocin (Wyeth)
8.9.3 Leading Penicillin Sales Forecasts
8.10 Quinolone Antibiotics
8.10.1 Avelox/Avalox (Astellas/Bayer/Schering-Plough)
8.10.2 Levaquin/Cravit and Floxin/Tarivid (Johnson & Johnson/Daiichi
Sankyo/Santen Pharmaceuticals)
8.10.3 Cipro/Ciprobay/Ciproxin (Bayer/Schering-Plough)
8.10.4 Leading Quinolone Sales Forecasts
8.11 Pleuromutilin Antibiotics
8.11.1 Altabax/Altargo (GlaxoSmithKline)
8.11.2 Leading Pleuromutilin Sales Forecasts
8.12 Other Antibiotics
8.13 Global Antibacterial Sales Forecasts
9 FUTURE BRANDS
9.1 Carbapenem Antibiotics
9.1.1 Faropenem Medoxomil (Replidyne)
9.1.2 PF-3,709,270 (Pfizer)
9.1.3 R1558 (Roche/Daiichi-Sankyo)
9.2 Cephalosporin Antibiotics
9.2.1 Ceftobiprole (J&J/[Basilea])
9.2.2 Ceftaroline (Cerexa/[Takeda])
9.3 Dihydrofolate Reductase Inhibitor Antibiotics
9.3.1 Iclaprim (Arpida/[Roche])
9.3.2 AR-709 (Arpida)
9.4 Glycopeptide Antibiotics
9.4.1 Oritavancin (Targanta/[InterMune])
9.4.2 Telavancin (Astellas/Theravance)
9.4.3 Zeven (Pfizer/[Vicuron Pharmaceuticals])
9.5 Ketolide Antibiotics
9.5.1 Cethromycin (Advanced Life Sciences/[Abbott])
9.6 Macrolides
9.6.1 S-013420 (Shionogi/[Enanta Pharmaceuticals])
9.6.2 Quinolone
9.6.3 ABT-492 (Abbott/[Wakunga Pharmaceuticals])
9.6.4 DX-619 (Daiichi-Sankyo)
9.6.5 Gracevit (Daiichi-Sankyo)
9.6.6 Garenoxacin (Schering-Plough/[Toyama])
9.6.7 Olamufloxacin (Abbott)
9.7 Other Antibiotics
9.7.1 Aurograb (Novartis/[NeuTec])
9.7.2 Tifacogin (Novartis/[Chiron])
9.7.3 REP8839 (Replidyne)
9.8 Future Global Antibacterial Sales Forecasts
10 KEY COMPANY PROFILES
10.1 Advanced Life Sciences
10.2 Arpida Ltd
10.3 Basilea Pharmaceutica AG
10.4 Cerexa Inc.
10.5 Cubist Pharmaceuticals, Inc.
10.6 Targanta Therapeutics Corp.
10.7 Theravance
APPENDIX 3: Acronyms
TABLES
Table 2.1 Infectious Disease Leading Worldwide Health Burden
Table 4.1 Potential for Clinical Success
Table 6.1 Historical Sales of Leading Antibiotics 2001-2005
Table 7.1 Different Classes of Antibacterial Agents
Table 8.1 Common Bacterial Infections
Table 8.2 Sales Forecasts of Leading Aminoglycosides US$mn 2005A - 2012E
Table 8.3 Sales Forecasts of Leading Carbapenems US$2005-2012E
Table 8.4 Approved Cephalosporin Antibiotics
Table 8.5 Sales Forecasts of Cephalosporins US$mn 2005-2012E
Table 8.6 Sales Forecasts of Leading Glycopeptides US$mn 2005A - 2012E
Table 8.7 Sales Forecasts of Ketolide Antibiotics US$mn 2005 - 2012E
Table 8.8 Clinical Efficacy of Cubicin Versus Comparator on Pathogens
Table 8.9 Sales Forecasts of Leading Lipopeptides US$mn 2005A - 2012E
Table 8.10 Sales Forecasts of Leading Macrolides US$m 2005A - 2012E
Table 8.11 Sales Forecasts of Leading Oxazolidinones US$m 2005A - 2012E
Table 8.12 Approved Penicillins
Table 8.13 Sales Forecasts of Leading Penicillins US$m 2005A - 2012E
Table 8.14 Approved Quinolone Antibiotics
Table 8.15 Sales Forecasts of Leading Quinolones US$m 2005A - 2012E
Table 8.16 Sales Forecasts of Leading Pleuromutilins US$m 2005A - 2012E
Table 8.17 Sales Summary of Leading Antibacterial Agents (US$m) 2005 -
2012E
Table 9.1 Antibiotics in Clinical Development
Table 9.2 DX-619 Potent Quinolone in Vitro Against Gram Positive Pathogens
Table 9.3: Sales Summary of New Antibacterial Agents (US$m) 2005 - 2012E
FIGURES
Figure 3.1 MRSA Among ICU Patients in the US, 1995-2004
Figure 6.1 Global Anti-Infective Market 2006
Figure 6.2 Global Anti-Infective Market 2015
Figure 6.3 Antibacterial Sales Split - Drug Class Split 2006
Figure 6.4 Cephalosporin Antibiotics - Leading Drugs 2006
Figure 6.5 Macrolide Antibiotics - Leading Drugs 2006
Figure 6.6 Penicillin Antibiotics - Leading Drugs 2006
Figure 6.7 Quinolone Antibiotics - Leading Drugs 2006
Figure 6.8 Other Antibiotics - Leading Drugs 2006
Figure 6.9 The Major Players 2006
Figure 6.10 The Major Players 2012
Figure 6.11 Antibacterial Agents - Drug Class Split 2012
Figure 7.1 Site of Action of Leading Antibacterial Agents
Figure 9.1 Number of Drugs in Development to Treat Infectious Diseases
Figure 9.2 Schematic of Drug-resistant Pathogens and Market Opportunities
Figure 9.3 DX-619 Effective in Severe Infection Models Potent Quinolone in
Vitro Against Gram Positive Pathogens
Figure 9.4 DC-159a Effective in Severe RTI
「世界の抗菌剤市場：R&Dパイプライン・市場分析・競合環境 」は2007年08月28日にアローヘッド・パブリッシャーズ より発行されました。 当レポートは126 Pagesで構成され、税抜￥258,121より販売しています。
